Estée Lauder
No proof required
Up to $5,000
Claims opening soon
B
Bayer Inc.
A Canada-wide class action against Bayer Inc. alleges bleeding-related injuries from the prescription drug Xarelto®. A settlement approval hearing is scheduled for April 1, 2026.
Opening soonCanada-wideClaim deadline: Pending court decisionEstimated payout: Compensation pendingClaims not open yet
About this settlement
Alleged bleeding-related injuries from the use of the prescription drug Xarelto® marketed by Bayer Inc. in Canada.
The class action Tluchak (Estate) v Bayer Inc. alleges that Canadian residents outside Québec who used Xarelto® experienced bleeding-related injuries. Bayer denies the allegations. A Canada-wide settlement has been reached to resolve the Saskatchewan and Québec class actions, pending court approval. The settlement fund will compensate eligible claimants, specified family members, and governments for healthcare costs. A court hearing to approve the settlement is scheduled for April 1, 2026. If approved, all Canadian class proceedings will end. Claim details and deadlines will be provided after approval.
Who qualifies
- Canadian residents outside Québec prescribed and ingested Xarelto® in Canada before October 27, 2025.
- Specified family members eligible under provincial family compensation legislation.
- Provincial and territorial governments who paid healthcare costs on behalf of eligible individuals.
Compensation pending
Claim deadline: Pending court decision
Silk and Great Value
Proof required
Up to $300,000
72 days left
Audible
No proof required
Compensation pending
Claims opening soon
Government of Canada
Proof required
Up to $200,000
722 days left
Meta (Facebook)
No proof required
Up to $90
Claims opening soon
Ticketmaster
No proof required
Compensation pending
Claims opening soon